BACKGROUND: Deaths related to opioid overdose have increased in the past decade. Community-based pharmacy practitioners have worked toward overcoming logistic and cultural barriers to make naloxone distribution for overdose prevention a standard and accepted practice. OBJECTIVE: To describe outpatient naloxone dispensing practices, including methods by which practitioners implement dispensing programs, prescribing patterns that include targeted patient populations, barriers to successful implementation, and methods for patient education. METHODS: Interviews were conducted with providers to obtain insight into the practice of dispensing naloxone. Practitioners were based in community pharmacies or clinics in large metropolitan cities across the country. RESULTS: It was found that 33% of participating pharmacists practice in a community-pharmacy setting, and 67% practice within an outpatient clinic-based location. Dispensing naloxone begins by identifying patient groups that would benefit from access to the antidote. These include licit users of high-dose prescription opioids (50%) or injection drug users and abusers of prescription medications (83%). Patients were identified through prescription records or provider screening tools. Dispensing naloxone required a provider's prescription in 5 of the 6 locations identified. Only 1 pharmacy was able to exercise pharmacist prescriptive authority within their practice. CONCLUSION: Outpatient administration of intramuscular and intranasal naloxone represents a means of preventing opioid-related deaths. Pharmacists can play a vital role in contacting providers, provision of products, education of patients and providers, and dissemination of information throughout the community. Preventing opioid overdose-related deaths should become a major focus of the pharmacy profession.
BACKGROUND: Deaths related to opioid overdose have increased in the past decade. Community-based pharmacy practitioners have worked toward overcoming logistic and cultural barriers to make naloxone distribution for overdose prevention a standard and accepted practice. OBJECTIVE: To describe outpatientnaloxone dispensing practices, including methods by which practitioners implement dispensing programs, prescribing patterns that include targeted patient populations, barriers to successful implementation, and methods for patient education. METHODS: Interviews were conducted with providers to obtain insight into the practice of dispensing naloxone. Practitioners were based in community pharmacies or clinics in large metropolitan cities across the country. RESULTS: It was found that 33% of participating pharmacists practice in a community-pharmacy setting, and 67% practice within an outpatient clinic-based location. Dispensing naloxone begins by identifying patient groups that would benefit from access to the antidote. These include licit users of high-dose prescription opioids (50%) or injection drug users and abusers of prescription medications (83%). Patients were identified through prescription records or provider screening tools. Dispensing naloxone required a provider's prescription in 5 of the 6 locations identified. Only 1 pharmacy was able to exercise pharmacist prescriptive authority within their practice. CONCLUSION:Outpatient administration of intramuscular and intranasal naloxone represents a means of preventing opioid-related deaths. Pharmacists can play a vital role in contacting providers, provision of products, education of patients and providers, and dissemination of information throughout the community. Preventing opioid overdose-related deaths should become a major focus of the pharmacy profession.
Authors: Erik D Barton; Christopher B Colwell; Timothy Wolfe; Dave Fosnocht; Craig Gravitz; Tamara Bryan; Will Dunn; Jeff Benson; Jeff Bailey Journal: J Emerg Med Date: 2005-10 Impact factor: 1.484
Authors: Anne-Maree Kelly; Debra Kerr; Paul Dietze; Ian Patrick; Tony Walker; Zeff Koutsogiannis Journal: Med J Aust Date: 2005-01-03 Impact factor: 7.738
Authors: Erik D Barton; Joseph Ramos; Christopher Colwell; Jeff Benson; Jeff Baily; William Dunn Journal: Prehosp Emerg Care Date: 2002 Jan-Mar Impact factor: 3.077
Authors: Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi Journal: JAMA Date: 2008-12-10 Impact factor: 56.272
Authors: Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff Journal: BMJ Date: 2013-01-30
Authors: Anilga Tabibian; Karen B Grothe; Manpreet S Mundi; Todd A Kellogg; Matthew M Clark; Cynthia O Townsend Journal: Obes Surg Date: 2015-10 Impact factor: 4.129
Authors: Mandy L Renfro; Leticia R Moczygemba; Jennifer Baumgartner; Glen Baumgart; Lucas G Hill Journal: Am J Pharm Educ Date: 2020-10 Impact factor: 2.047
Authors: Sean T Allen; Rebecca Hamilton White; Allison O'Rourke; Suzanne M Grieb; Michael E Kilkenny; Susan G Sherman Journal: Drug Alcohol Depend Date: 2019-09-21 Impact factor: 4.492
Authors: Andrea Jakubowski; Alexander Pappas; Lee Isaacsohn; Felipe Castillo; Mariya Masyukova; Richard Silvera; Louisa Holaday; Evan Rausch; Sameen Farooq; Keith T Veltri; Chinazo O Cunningham; Marcus A Bachhuber Journal: Subst Abus Date: 2018-11-26 Impact factor: 3.716
Authors: Stefanie J Logothetis; Matthew E Borrego; Melissa H Roberts; Amy Bachyrycz; Graham S Timmins; Bernadette Jakeman Journal: J Am Pharm Assoc (2003) Date: 2018-09-28